非酒精性脂肪性肝病家族风险评分用于检测进展性纤维化的开发与验证:一项前瞻性多中心研究
本研究为前瞻性横断面家族研究,在加利福尼亚圣迭戈衍生队列和芬兰赫尔辛基验证队列中,纳入242例先证者及其396名一级亲属,开发并验证NAFLD家族风险评分。评分由年龄、2型糖尿病、肥胖及先证者NAFLD合并进展性纤维化构成,验证队列中检测进展性纤维化的AUC为0.94,优于FIB-4指数(AUC 0.94 vs 0.70,P=0.02)。
要点
- NAFLD家族风险评分由年龄、2型糖尿病、肥胖及先证者NAFLD合并进展性纤维化构成。
- 验证队列中评分检测进展性纤维化的AUC为0.94,优于FIB-4指数(0.70,P=0.02)。
- 该评分是识别一级亲属中进展性纤维化的简单准确工具。
核心结论
- NAFLD家族风险评分是识别一级亲属中进展性纤维化的简单准确临床工具。
- 这些数据可能对NAFLD的监测具有意义。
研究设计与样本
- 前瞻性横断面家族研究,衍生队列来自加利福尼亚圣迭戈,验证队列来自芬兰赫尔辛基。
- 纳入连续成人先证者242例(NAFLD合并进展性纤维化、NAFLD无进展性纤维化及非NAFLD),每例至少1名一级亲属。
- 所有纳入的先证者及一级亲属均接受肝纤维化评估,多数采用磁共振弹性成像。
主要发现
- 共纳入396名一级亲属(64%为男性),中位年龄47岁(四分位距32-62岁),中位体重指数27.6 kg/m2(四分位距24.1-32.5 kg/m2)。
- 衍生队列(n=220)中,年龄(1分)、2型糖尿病(1分)、肥胖(2分)及先证者NAFLD合并进展性纤维化(2分)为一级亲属进展性纤维化的预测因素。
- 验证队列(n=176)中,NAFLD家族风险评分检测进展性纤维化的受试者工作特征曲线下面积为0.94。
- 验证队列中,NAFLD家族风险评分优于FIB-4指数(受试者工作特征曲线下面积0.94 vs 0.70;P=0.02)。
关键数值与推荐
- NAFLD家族风险评分组成:年龄1分,2型糖尿病1分,肥胖2分,先证者NAFLD合并进展性纤维化2分。
- 验证队列中检测进展性纤维化的AUC为0.94,FIB-4指数为0.70(P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD)-related fibrosis is heritable, but it is unclear how family history may be used to identify first-degree relatives with advanced fibrosis. We aimed to develop and validate a simple risk score to identify first-degree relatives of probands who have undergone assessment of liver fibrosis who are at higher risk of NAFLD with advanced fibrosis. METHODS: This prospective, cross-sectional, familial study consisted of a derivation cohort from San Diego, California, and a validation cohort from Helsinki, Finland. This study included consecutive adult probands (n = 242) with NAFLD and advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD, with at least 1 of their first-degree relatives. All included probands and first-degree relatives underwent evaluation of liver fibrosis, the majority by magnetic resonance elastography. RESULTS: A total of 396 first-degree relatives (64% male) were included. The median age and body mass index were 47 years (interquartile range, 32-62 y) and 27.6 kg/m2 (interquartile range, 24.1-32.5 kg/m2), respectively. Age (1 point), type 2 diabetes (1 point), obesity (2 points), and proband with NAFLD and advanced fibrosis (2 points) were predictors of advanced fibrosis among first-degree relatives in the derivation cohort (n = 220) and formed the NAFLD Familial Risk Score. The area under the receiver operator characteristic curve of the NAFLD Familial Risk Score for detecting advanced fibrosis was 0.94 in the validation cohort (n = 176). The NAFLD Familial Risk Score outperformed the Fibrosis-4 index in the validation cohort (area under the receiver operator characteristic curve, 0.94 vs 0.70; P = .02). CONCLUSIONS: The NAFLD Familial Risk Score is a simple and accurate clinical tool to identify advanced fibrosis in first-degree relatives. These data may have implications for surveillance in NAFLD.
引用
- Huang DQ, Ahlholm N, Luukkonen PK, et al. Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study. Clin Gastroenterol Hepatol. 2023. PMID: 37406954. doi:10.1016/j.cgh.2023.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。